Compare TDOC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | CTMX |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.7M | 977.1M |
| IPO Year | 2015 | 2015 |
| Metric | TDOC | CTMX |
|---|---|---|
| Price | $5.45 | $4.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | $7.50 | ★ $12.10 |
| AVG Volume (30 Days) | 4.4M | ★ 10.0M |
| Earning Date | 04-29-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | $76,201,000.00 |
| Revenue This Year | $1.27 | N/A |
| Revenue Next Year | $1.25 | $27.22 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $0.40 |
| 52 Week High | $9.77 | $8.21 |
| Indicator | TDOC | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 48.64 |
| Support Level | $4.44 | $3.55 |
| Resistance Level | $5.49 | $6.20 |
| Average True Range (ATR) | 0.22 | 0.61 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 53.17 | 15.74 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.